Normobaric Hyperoxia

Phase 2Small molecule

GGaylan Rockswold

Normobaric Hyperoxia is one of 68 small molecule programs targeting Brain Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain InjuryActive, not recruiting

Ischemic StrokeActive, not recruiting

Brain InjuryPhase 2

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

2 2

Repatha

Amgen

Preclinical

2 3

Levaquin

WWim Janssens

Preclinical

3 4

Normobaric Hyperoxia

GGaylan Rockswold

Phase 2

2 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Brain Injury

NCT02407028

Clinical

Trials by Indication[1]

Ischemic stroke2 trials

Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke

Completed·—·N/A·NCT03620370·86 enrolled

Normobaric Hyperoxia Combined With Endovascular Treatment in Acute Ischemic Stroke (OPENS-2)

Completed·—·Phase 2·NCT04681651·282 enrolled

Brain Injury1 trial

Hyperbaric Oxygen Brain Injury Treatment Trial

Recruiting·GGaylan Rockswold·Phase 2·NCT02407028·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Normobaric Hyperoxia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Normobaric Hyperoxia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Normobaric Hyperoxia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gaylan Rockswold company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGaylan Rockswold

Normobaric Hyperoxia

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Ischemic stroke2 trials

Brain Injury1 trial

References

Drug Info

Quick Facts

Related News